{"id":4363,"date":"2019-03-01T16:39:33","date_gmt":"2019-03-01T11:09:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4363"},"modified":"2025-05-07T12:38:09","modified_gmt":"2025-05-07T07:08:09","slug":"cost-ineffective-orphan-drugs-limit-the-access","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access","title":{"rendered":"Cost ineffective Orphan Drugs limit the access"},"content":{"rendered":"\n

Rare diseases<\/strong> are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens. In addition, only a few of them have effective drug treatment available. The European Union <\/strong>(EU) definition of a rare disease is one that affects fewer than 5 in 10,000 people. These affect 6\u20138% (or about 30 million people) out of the 508 million population of <\/strong>EU countries. So, pharmaceutical companies refrain from investing in them.<\/p>\n\n\n\n

This the reason they are called orphan drugs as they are not commercially viable. <\/strong>When medicine is granted an orphan designation, various incentives are provided to the sponsor of the clinical trial.<\/p>\n\n\n\n

Treatment <\/strong>for Rare Diseases is still a major obstacle which we need to overcome. Out of 6000 known rare diseases, cures for only 200 are known.<\/strong><\/p>\n\n\n\n

Fortunately, in recent years, pharmaceutical companies have made advancements in developing drugs for Rare Diseases.<\/strong> The reason being improvements in technology to identify the causes behind them. The financial aid provided for their clinical trials which has resulted in more than 400 drugs getting approved. Also, the global orphan drug market is estimated to reach USD 209 billion by 2022 accounting for 21.4% of total branded prescription drug sales.<\/p>\n\n\n\n

 But their high prices confine the patients\u2019\naccess and make it impossible to bear by any health-care system as well. <\/p>\n\n\n\n

For instance, Nusinersen<\/strong>, an antisense oligonucleotide, is given via intrathecal injection, at a cost of USD 125000 per injection. And the whole treatment costs a lot more than this. Imiglucerase<\/strong>, an enzyme replacement therapy to treat Gaucher\u2019s disease<\/a><\/strong>, might cost as much as USD 400,000 per year for an adult patient. Eculizumabt<\/strong>, which treats Paroxysmal Nocturnal Hemoglobinuria<\/a><\/strong> costs up to USD 500,000 per patient per year.<\/p>\n\n\n\n

The monopoly\nof pharmaceutical companies in any specific drug making, patent rights, sparse estimates\nof the cost of development, less knowledge of the drug are some of the reasons behind\nhigher prices of the orphan drug.<\/p>\n\n\n\n

With the high unmet drug needs\nand the absence of substitutes, the cost factor becomes more of a bigger problem.\n<\/strong><\/p>\n\n\n\n

Although\nthe policymakers have started paying attention to the unaffordable prices of these\ndrugs but there is still more to be implemented in this area. The components on\nwhich the cost is based and made available to patients is one thing to be kept\nin mind. Broad and sustainable access to DRUGS is important. A global and\ncohesive strategy is needed while deciding the pricing of treatment. Drugs\u2019\nprices need to be regulated carefully. <\/p>\n\n\n\n

Because\nin the end providing affordable health care should be the priority of the\ncompanies and policymakers.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens. In addition, only a few of them have effective drug treatment available. The European Union (EU) definition of a rare disease is one that affects fewer than 5 in 10,000 people. These affect 6\u20138% (or about 30 million […]<\/p>\n","protected":false},"author":1,"featured_media":4377,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[169,2701,2695,216,2698,849,2696,2697,2694,2693,2699,502,2700],"industry":[17225],"therapeutic_areas":[17234],"class_list":["post-4363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-clinical-trials","tag-cost","tag-cures","tag-drug","tag-eculizumabt","tag-european-union","tag-gauchers-disease","tag-imiglucerase","tag-nusinersen","tag-orphan-drugs","tag-paroxysmal-nocturnal-hemoglobinuria","tag-rare-disease","tag-usd","industry-pharmaceutical","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nWhat are the obstacles in finidng cure for Rare Diseases? | DelveInsight<\/title>\n<meta name=\"description\" content=\"Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What are the obstacles in finidng cure for Rare Diseases? | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-01T11:09:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T07:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"485\" \/>\n\t<meta property=\"og:image:height\" content=\"424\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"What are the obstacles in finidng cure for Rare Diseases? | DelveInsight","description":"Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access","og_locale":"en_US","og_type":"article","og_title":"What are the obstacles in finidng cure for Rare Diseases? | DelveInsight","og_description":"Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens.","og_url":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-01T11:09:33+00:00","article_modified_time":"2025-05-07T07:08:09+00:00","og_image":[{"width":485,"height":424,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access","url":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access","name":"What are the obstacles in finidng cure for Rare Diseases? | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4.png","datePublished":"2019-03-01T11:09:33+00:00","dateModified":"2025-05-07T07:08:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/cost-ineffective-orphan-drugs-limit-the-access#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4.png","width":485,"height":424},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09173426\/Capture4-300x262.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cost<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eculizumabt<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">European Union<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gaucher\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Imiglucerase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Nusinersen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">orphan drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Paroxysmal Nocturnal Hemoglobinuria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">USD<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Clinical trials<\/span>","<span class=\"advgb-post-tax-term\">cost<\/span>","<span class=\"advgb-post-tax-term\">cures<\/span>","<span class=\"advgb-post-tax-term\">Drug<\/span>","<span class=\"advgb-post-tax-term\">Eculizumabt<\/span>","<span class=\"advgb-post-tax-term\">European Union<\/span>","<span class=\"advgb-post-tax-term\">Gaucher\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Imiglucerase<\/span>","<span class=\"advgb-post-tax-term\">Nusinersen<\/span>","<span class=\"advgb-post-tax-term\">orphan drugs<\/span>","<span class=\"advgb-post-tax-term\">Paroxysmal Nocturnal Hemoglobinuria<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">USD<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Mar 1, 2019","modified":"Updated on May 7, 2025"},"absolute_dates_time":{"created":"Posted on Mar 1, 2019 4:39 pm","modified":"Updated on May 7, 2025 12:38 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4363"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4363\/revisions"}],"predecessor-version":[{"id":31824,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4363\/revisions\/31824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4377"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4363"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4363"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}